Abingworth, a venture capital group supported by Carlyle, is reportedly establishing a new fund with a target of $1.5 billion to finance late-stage clinical trials. The fund is expected to support up to eight clinical studies, potentially forging partnerships with large pharmaceutical companies to share royalties from resulting products.
While Abingworth has remained tight-lipped regarding the new fund, industry reports suggest that the initiative aligns with the firm's recent investment activities, which have increasingly focused on late-stage assets with clear paths to market. The fund's structure would allow Abingworth to invest in promising therapies while mitigating risk through partnerships and royalty-based returns. This approach could address the growing need for capital to advance clinical programs, particularly in an environment where traditional funding sources may be constrained.
